Cross-talk between tumors can affect responses to therapy

Advanced stages of cancer often involve multiple tumors in different locations in the body. These tumors are associated with a microenvironment that can influence tumor responses to immunotherapy. Whether tumors and their disparate microenvironment can interact together at distance in a multiple tumor setting, through a form of cross-talk, and affect their responses to immunotherapy has never been described. Our study investigated the cross-talk between two tumors with disparate microenvironments in a mouse model. We demonstrated that immunosuppressive visceral tumors could influence distant subcutaneous (SC) tumors to render them resistant to immunotherapy. We observed distinct modifications in the SC tumor microenvironment following cross-talk with kidney tumors that exhibit a type-2 macrophage-related immunosuppressive microenvironment. Indeed, when a concomitant kidney tumor was present in the mouse, the SC tumors were highly infiltrated with M2 macrophages and had a reduced T cell and NK cell effector immune profile. Finally, blocking the M2-associated chemokine CCL2 or depleting macrophages, significantly improved the effect of immunotherapy on growth of SC tumors in the presence of concomitant kidney tumors. This work emphasizes the potential negative influence that a tumor, with a strong immunosuppressive microenvironment, can exert on distant tumors that would normally be treatment-responsive. This report may lead to a new vision of the prioritization in the treatment of advanced metastatic cancer.

[1]  Jorge Joven,et al.  CCL2 Shapes Macrophage Polarization by GM-CSF and M-CSF: Identification of CCL2/CCR2-Dependent Gene Expression Profile , 2014, The Journal of Immunology.

[2]  Deepak Mittal,et al.  New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. , 2014, Current opinion in immunology.

[3]  E. Elinav,et al.  Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms , 2013, Nature Reviews Cancer.

[4]  R. Montironi,et al.  Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma , 2013, Cancer Immunology, Immunotherapy.

[5]  F. Schuetz,et al.  B cell-regulated immune responses in tumor models and cancer patients , 2013, Oncoimmunology.

[6]  B. Lippitz,et al.  Cytokine patterns in patients with cancer: a systematic review. , 2013, The Lancet. Oncology.

[7]  H. Moch,et al.  Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma , 2013, Oncoimmunology.

[8]  J. Hamilton,et al.  Colony stimulating factors and myeloid cell biology in health and disease. , 2013, Trends in immunology.

[9]  W. Linehan,et al.  Outcomes of patients with surgically treated bilateral renal masses and a minimum of 10 years of followup. , 2012, The Journal of urology.

[10]  N. Restifo,et al.  Cellular constituents of immune escape within the tumor microenvironment. , 2012, Cancer research.

[11]  L. Zitvogel,et al.  Abscopal but desirable , 2012, Oncoimmunology.

[12]  P. Watson,et al.  CD20+ Tumor-Infiltrating Lymphocytes Have an Atypical CD27− Memory Phenotype and Together with CD8+ T Cells Promote Favorable Prognosis in Ovarian Cancer , 2012, Clinical Cancer Research.

[13]  Douglas Hanahan,et al.  Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment Prospects and Obstacles for Therapeutic Targeting of Function-enabling Stromal Cell Types , 2022 .

[14]  Jedd D. Wolchok,et al.  Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.

[15]  Steven L Salzberg,et al.  Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.

[16]  L. Coussens,et al.  Differential macrophage programming in the tumor microenvironment. , 2012, Trends in immunology.

[17]  Hong Peng,et al.  Interactions between cancer stem cells and their niche govern metastatic colonization , 2011, Nature.

[18]  T. Wynn,et al.  Protective and pathogenic functions of macrophage subsets , 2011, Nature Reviews Immunology.

[19]  R. Geffers,et al.  Macrophages at the Fetal–Maternal Interface Express Markers of Alternative Activation and Are Induced by M-CSF and IL-10 , 2011, The Journal of Immunology.

[20]  J. Tímár,et al.  Prognostic impact of B-cell density in cutaneous melanoma , 2011, Cancer Immunology, Immunotherapy.

[21]  Marcel Martin Cutadapt removes adapter sequences from high-throughput sequencing reads , 2011 .

[22]  R. Schreiber,et al.  Natural innate and adaptive immunity to cancer. , 2011, Annual review of immunology.

[23]  Zhao-You Tang,et al.  Depletion of Tumor-Associated Macrophages Enhances the Effect of Sorafenib in Metastatic Liver Cancer Models by Antimetastatic and Antiangiogenic Effects , 2010, Clinical Cancer Research.

[24]  R. Schwendener,et al.  Toll-Like Receptor Triggering and T-Cell Costimulation Induce Potent Antitumor Immunity in Mice , 2009, Clinical Cancer Research.

[25]  Wanling Xie,et al.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Axel Hoos,et al.  Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.

[27]  Matthew J. Craig,et al.  CCL2 and Interleukin-6 Promote Survival of Human CD11b+ Peripheral Blood Mononuclear Cells and Induce M2-type Macrophage Polarization* , 2009, The Journal of Biological Chemistry.

[28]  S. Amini,et al.  Monocyte chemoattractant protein-1 (MCP-1): an overview. , 2009, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[29]  C. Yeh,et al.  Effector/Memory but Not Naive Regulatory T Cells Are Responsible for the Loss of Concomitant Tumor Immunity1 , 2009, The Journal of Immunology.

[30]  Paula D. Bos,et al.  Metastasis: from dissemination to organ-specific colonization , 2009, Nature Reviews Cancer.

[31]  Lior Pachter,et al.  Sequence Analysis , 2020, Definitions.

[32]  T. Whiteside The tumor microenvironment and its role in promoting tumor growth , 2008, Oncogene.

[33]  P. Allavena,et al.  Macrophage polarization in tumour progression. , 2008, Seminars in cancer biology.

[34]  P. Allavena,et al.  The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. , 2008, Critical reviews in oncology/hematology.

[35]  K. Czene,et al.  Incidence and prognosis of synchronous and metachronous bilateral breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  A. Sica,et al.  Altered macrophage differentiation and immune dysfunction in tumor development. , 2007, The Journal of clinical investigation.

[37]  L. Coussens,et al.  Humoral immunity, inflammation and cancer. , 2007, Current opinion in immunology.

[38]  A. Poggi,et al.  Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells , 2006, Archivum Immunologiae et Therapiae Experimentalis.

[39]  T. Whiteside,et al.  Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. , 2006, Seminars in cancer biology.

[40]  E. Esplugues,et al.  Title: Induction of Tumor Nk Cell Immunity by Anti-cd69 Antibody Therapy , 2022 .

[41]  S. Rosenberg,et al.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  S. Fosså,et al.  Chemotherapy in metastatic renal cell cancer , 2005, World Journal of Urology.

[43]  R. Schreiber,et al.  The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.

[44]  E. Esplugues,et al.  Enhanced Antitumor Immunity in Mice Deficient in CD69 , 2003, The Journal of experimental medicine.

[45]  Elise C. Kohn,et al.  The microenvironment of the tumour–host interface , 2001, Nature.

[46]  S. Rosenberg,et al.  Patients With Melanoma Metastases at Cutaneous and Subcutaneous Sites Are Highly Susceptible to Interleukin-2–Based Therapy , 2001, Journal of immunotherapy.

[47]  M. Loda,et al.  Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1 , 2000, Nature.

[48]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[49]  G. Murphy,et al.  A murine renal cell carcinoma. , 1973, Journal of the National Cancer Institute.

[50]  J. Flynn,et al.  Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[51]  G. Kroemer,et al.  2012 Landes Bioscience. Do not distribute. Abscopal but desirable The contribution of immune responses to the efficacy of radiotherapy , 2012 .

[52]  L. Coussens,et al.  Paradoxical roles of the immune system during cancer development , 2006, Nature Reviews Cancer.